Active substance
Results for the substance mogamulizumab
1 result
About this active substance
Mogamulizumab is a monoclonal antibody used for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell leukemia (PTCL). It works by targeting the CCR4 receptor on the surface of cancer cells, stimulating the immune system to destroy them.
The medication is administered via intravenous infusion, usually once weekly during the initial treatment cycles, and later at longer intervals. Common side effects include skin rashes, fatigue, nausea, and infections.
Mogamulizumab is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. Its use also requires careful monitoring to prevent severe adverse reactions, such as cytokine release syndrome.
This medication is an important option for patients with CTCL or PTCL, helping to reduce disease progression and improve their quality of life.
The medication is administered via intravenous infusion, usually once weekly during the initial treatment cycles, and later at longer intervals. Common side effects include skin rashes, fatigue, nausea, and infections.
Mogamulizumab is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. Its use also requires careful monitoring to prevent severe adverse reactions, such as cytokine release syndrome.
This medication is an important option for patients with CTCL or PTCL, helping to reduce disease progression and improve their quality of life.